• 1
    van Emmerik-van Oortmerssena K., van de Glind G., van den Brink W., Smit F., Crunelle C. L., Swets M. et al. Prevalence of attention-deficit hyperactivity disorder in substance use disorder patients: a meta-analysis and meta-regression analysis. Drug Alcohol Depend 2012; 122: 1119.
  • 2
    Ginsberg Y., Hirvikoski T., Lindefors N. Attention deficit hyperactivity disorder (ADHD) among longer-term prison inmates is a prevalent, persistent and disabling disorder. BMC Psychiatry 2010; 10: 112.
  • 3
    Konstenius M., Larsson H., Lundholm L., Philips B., van de Glind G., Jayaram-Lindström N. et al. An epidemiological study of ADHD, substance use, and comorbid problems in incarcerated women in Sweden. J Atten Disord 2012; doi: 10.1177/1087054712451126 [E-pub ahead of print].
  • 4
    Rosler M., Retz W., Retz-Junginger P., Hengesch G., Schneider M., Supprian T. et al. Prevalence of attention deficit-/hyperactivity disorder (ADHD) and comorbid disorders in young male prison inmates. Eur Arch Psychiatry Clin Neurosci 2004; 254: 365371.
  • 5
    Young S. J., Adamou M., Bolea B., Gudjonsson G., Muller U., Pitts M. et al. The identification and management of ADHD offenders within the criminal justice system: a consensus statement from the UK Adult ADHD Network and criminal justice agencies. BMC Psychiatry 2011; 11: 32.
  • 6
    Adler L. A., Zimmerman B., Starr H. L., Silber S., Palumbo J., Orman C. et al. Efficacy and safety of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder: a randomized, placebo-controlled, double-blind, parallel group, dose-escalation study. J Clin Psychopharmacol 2009; 29: 239247.
  • 7
    Biederman J., Mick E., Surman C., Doyle R., Hammerness P., Harpold T. et al. A randomized, placebo-controlled trial of OROS methylphenidate in adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2006; 59: 829835.
  • 8
    Spencer T., Biederman J., Wilens T., Doyle R., Surman C., Prince J. et al. A large, double-blind, randomized clinical trial of methylphenidate in the treatment of adults with attention-deficit/hyperactivity disorder. Biol Psychiatry 2005; 57: 456463.
  • 9
    Levin F. R., Evans S. M., Brooks D. J., Garawi F. Treatment of cocaine dependent treatment seekers with adult ADHD: double-blind comparison of methylphenidate and placebo. Drug Alcohol Depend 2007; 87: 2029.
  • 10
    Levin F. R., Evans S. M., Brooks D. J., Kalbag A. S., Garawi F., Nunes E. V. et al. Treatment of methadone-maintained patients with adult ADHD: double-blind comparison of methylphenidate, bupropion and placebo. Drug Alcohol Depend 2006; 81: 137148.
  • 11
    Schubiner H., Saules K. K., Arfken C. L., Johanson C. E., Schuster C. R., Lockhart N. et al. Double-blind placebo-controlled trial of methylphenidate in the treatment of adult ADHD patients with comorbid cocaine dependence. Exp Clin Psychopharmacol 2002; 10: 286294.
  • 12
    Konstenius M., Jayaram-Lindstrom N., Beck O., Franck J. Sustained release methylphenidate for the treatment of ADHD in amphetamine abusers: a pilot study. Drug Alcohol Depend 2010; 108: 130133.
  • 13
    United Nations Office on Drugs and Crime (UNODC). World Drug Report. (United Nations publication, Sales No. E.12.XI.1).
  • 14
    Jayaram-Lindstrom N., Hammarberg A., Beck O., Franck J. Naltrexone for the treatment of amphetamine dependence: a randomized, placebo-controlled trial. Am J Psychiatry 2008; 165: 14421448.
  • 15
    Kaye S., Darke S., Torok M. Attention deficit hyperactivity disorder (ADHD) among illicit psychostimulant users: a hidden disorder? Addiction 2013; 108: 923931.
  • 16
    Matsumoto T., Kamijo A., Yamaguchi A., Iseki E., Hirayasu Y. Childhood histories of attention-deficit hyperactivity disorders in Japanese methamphetamine and inhalant abusers: preliminary report. Psychiatry Clin Neurosci 2005; 59: 102105.
  • 17
    Wilens T. E., Morrison N. R., Prince J. An update on the pharmacotherapy of attention-deficit/hyperactivity disorder in adults. Expert Rev Neurother 2011; 11: 14431465.
  • 18
    Volkow N. D., Fowler J. S., Wang G. J., Swanson J. M. Dopamine in drug abuse and addiction: results from imaging studies and treatment implications. Mol Psychiatry 2004; 9: 557569.
  • 19
    Liebrenz M., Hof D., Buadze A., Stohler R., Eich D. High dose methylphenidate treatment in adult attention deficit hyperactivity disorder: a case report. J Med Case Rep 2012; 6: 125129.
  • 20
    Hakansson A., Schlyter F., Berglund M. Characteristics of primary amphetamine users in Sweden: a criminal justice population examined with the Addiction Severity Index. Eur Addict Res 2009; 15: 1018.
  • 21
    American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, 4th ed. Washington, DC: American Psychiatric Press, Inc.; 1994.
  • 22
    Kessler R. C., Adler L., Ames M., Johanson C. E., Schuster C. R., Lockhart N. et al. The World Health Organization Adult ADHD Self-Report Scale (ASRS): a short screening scale for use in the general population. Psychol Med 2005; 35: 245256.
  • 23
    Ward M. F., Wender P. H., Reimherr F. W. The Wender Utah Rating Scale: an aid in the retrospective diagnosis of childhood attention deficit hyperactivity disorder. Am J Psychiatry 1993; 150: 885890.
  • 24
    First M. B., Gibbon M., Spitzer R. L., Williams J. B. W., Benjamin L. S. Structured Clinical Interview for DSM-IV Axis II Personality Disorders (SCID-II). Washington, DC: American Psychiatric Press, Inc.; 1997.
  • 25
    McLellan A. T., Kushner H., Metzger D., Peters R., Smith I., Grissom G. et al. The fifth edition of the Addiction Severity Index. J Subst Abuse Treat 1992; 9: 199213.
  • 26
    Conners C., Erhardt D., Sparrow E. Conners' Adult ADHD Rating Scales (CAARS): Technical Manual. North Tonawanda, NY: Multi-Health Systems Inc.; 1999.
  • 27
    Wechsler D. WAIS-III Administration and Scoring Manual. San Antonio, TX: The Psychological Corporation; 1997.
  • 28
    International Conference on Harmonization (ICH). Guideline for Good Clinical Practice. 2002.
  • 29
    World Medical Organization. Available at:
  • 30
    Caroll K. A Cognitive-Behavioral Approach: Treating Cocaine Addiction. NIH Publication no. 98-4308. Rockville, MD: National Institute on Drug Abuse; 1998.
  • 31
    Lambert M. J., Burlingame G. M., Umphress V., Hansen N. B., Vermeersch D. A., Clouse G. C. The reliability and validity of the Outcome Questionnaire. Clin Psychol Psychother 1996; 3: 249258.
  • 32
    Gustavsson E., Andersson M., Stephanson N., Beck O. Validation of direct injection electrospray LC-MS/MS for confirmation of opiates in urine drug testing. J Mass Spectrom 2007; 42: 881889.
  • 33
    Karlsson A., Gustavsson H., Mansson S., McAuley K. B., Back S. A. Dose integration characteristics in normoxic polymer gel dosimetry investigated using sequential beam irradiation. Phys Med Biol 2007; 52: 46974706.
  • 34
    Love A., James D., Willner P. A comparison of two alcohol craving questionnaires. Addiction 1998; 93: 10911102.
  • 35
    Gordon M. S., Kinlock T. W., Schwartz R. P., O'Grady K. E. A randomized clinical trial of methadone maintenance for prisoners: findings at 6 months post-release. Addiction 2008; 103: 13331342.
  • 36
    Kinlock T. W., Battjes R. J., Schwartz R. P. A novel opioid maintenance program for prisoners: report of post-release outcomes. Am J Drug Alcohol Abuse 2005; 31: 433454.
  • 37
    Ginsberg Y., Lindefors N. Methylphenidate treatment of adult male prison inmates with attention-deficit hyperactivity disorder: randomised double-blind placebo-controlled trial with open-label extension. Br J Psychiatry 2012; 200: 6873.
  • 38
    Roache J. D., Grabowski J., Schmitz J. M., Creson D. L., Rhoades H. M. Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment. J Clin Psychopharmacol 2000; 20: 6168.
  • 39
    Volkow N. D., Wang G. J., Newcorn J., Telang F., Solanto M. V., Fowler J. S. et al. Depressed dopamine activity in caudate and preliminary evidence of limbic involvement in adults with attention-deficit/hyperactivity disorder. Arch Gen Psychiatry 2007; 64: 932940.
  • 40
    Parasrampuria D. A., Schoedel K. A., Schuller R., Silber S. A., Ciccone P. E., Gu J. et al. Do formulation differences alter abuse liability of methylphenidate? A placebo-controlled, randomized, double-blind, crossover study in recreational drug users. J Clin Psychopharmacol 2007; 27: 459467.
  • 41
    Lichtenstein P., Halldner L., Zetterqvist J., Sjolander A., Serlachius E., Fazel S. et al. Medication for attention deficit-hyperactivity disorder and criminality. N Engl J Med 2012; 367: 20062014.
  • 42
    Hammerness P. G., Wilens T. E., Berul C. I., Elkort M. S. Supraventricular tachycardia in an adolescent with attention-deficit/hyperactivity disorder (ADHD). J Am Acad Child Adolesc Psychiatry 2008; 47: 219220.
  • 43
    Stevens J. R., George R. A., Fusillo S., Stern T. A., Wilens T. E. Plasma methylphenidate concentrations in youths treated with high-dose osmotic release oral system formulation. J Child Adolesc Psychopharmacol 2010; 20: 4954.